Israeli biomedical innovations company BioLight Life Sciences Investment, through its IOPtima subsidiary, has signed an exclusive distribution deal to sell its trademark glaucoma treatment system in China, the company announced in a press release.
Using CO2 laser technology, the IOPtiMate introduces a unique, more effective glaucoma treatment method. The gas laser's properties help reduce eye pressure by letting aqueous humor flow in and allowing surgeons to thin the sclera by taking away tissue layer by layer.
The intact scleral tissue layer that remains is thin enough to relieve the eye of excessive pressure. Meanwhile, the aqueous solutions in the eye absorb the CO2 laser's radiation, preventing it from damaging the eye. This in turn reduces the risk of post-surgery complications and side effects.
The introduction of the system was approved by the China Food and Drug Administration in March. According to IOPtima, its four-year agreement with a well-known Chinese distributor of medical technology includes a commitment to the purchase of minimum 100 systems once the technology is introduced to the market. Leading ophthalmologists and medical centers throughout China are reported to be among the confirmed buyers. According to BioLight CEO Suzana Nahum-Zilberberg, the Chinese side's pledge to purchase so many systems during the initial term of the agreement reflects the belief of medical professionals in the company's technology.
Glaucoma is a chronic disease that causes blindness by damaging the optical nerve via pressure and usually requires lifelong treatment. Estimated to affect around 67 million people around the world, it is the second most common cause of blindness, as well as the reason for a worldwide drug therapy and surgery market worth $4 billion a year.